Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget’s Disease of Bone

• Published in: Calcified tissue international Vol. 101; no. 1; pp. 43 - 49
• Main Authors: Reid, Ian R., Maslowski, Katherine
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.07.2017; Springer Nature B.V
• Subjects: Aged; Aged, 80 and over; Alkaline phosphatase; Biochemical markers; Biochemistry; Biomedical and Life Sciences; Bone (long); Bone Density Conservation Agents - therapeutic use; Bone diseases; Cell Biology; Clinical outcomes; Diphosphonates - therapeutic use; Drug therapy; Endocrinology; Female; Humans; Imidazoles - therapeutic use; Intravenous administration; Life Sciences; Male; Medical imaging; Middle Aged; Minimal residual disease; Original Research; Orthopedics; Osteitis Deformans - diagnostic imaging; Osteitis Deformans - drug therapy; Paget's disease; Procollagen; Radionuclide Imaging; Scintigraphy; Time; Zoledronic acid; Scintigraphy; Bisphosphonates; Paget’s disease; Markers

Zoledronate produces long-term normalization of biochemical markers in Paget’s disease but whether this implies the absence of active disease is unknown. We have determined whether bone scintigraphy, a more sensitive index of disease activity, is also normalized ≥5 years after treatment with zoledro...